



## Clinical trial results:

### Evaluating the safeness of Agrippal S1 in preventing flu on Vietnamese volunteers.

#### Summary

EudraCT number	2014-005128-91
Trial protocol	Outside EU/EEA
Global end of trial date	04 March 2010

#### Results information

Result version number	v2 (current)
This version publication date	28 July 2016
First version publication date	03 May 2015
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Required for the re-QC project because of the EudraCT system glitch and possible updates to results may be required. Moreover, a change in system user for this study is necessary.
Summary attachment (see zip file)	V71_21 CTRD 13 Apr 15 (V71_21 CTRD 13 Apr 15.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	V71_21
-----------------------	--------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01123954
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Novartis Vaccines and Diagnostics S.r.l.
Sponsor organisation address	Via Fiorentina 1, Siena, Italy, 53100
Public contact	Posting Director, Novartis Vaccines and Diagnostics S.r.l., RegistryContactVaccinesUS@novartis.com
Scientific contact	Posting Director, Novartis Vaccines and Diagnostics S.r.l., RegistryContactVaccinesUS@novartis.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	27 April 2010
Is this the analysis of the primary completion data?	No

---

Global end of trial reached?	Yes
Global end of trial date	04 March 2010
Was the trial ended prematurely?	No

---

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To evaluate the safety of a single 0.5mL dose of Agrippal S1 administered to Vietnamese volunteers.

---

Protection of trial subjects:

This trial was performed with the ethical principles that have their origin in the Declaration of Helsinki, that are consistent with Good Clinical Practice (GCP) according to International Conference on Harmonisation (ICH) guidelines, the applicable regulatory requirements(s) for the country in which the study is conducted, and applicable standard operating procedures (SOPs). The benefits of the study were in proportion to the risks; the rights and welfare of the subjects were respected; the physicians conducting the trial did not find the hazards to outweigh the potential benefits.

---

Background therapy:

N/A

---

Evidence for comparator:

N/A

---

Actual start date of recruitment	29 January 2010
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

---

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Vietnam: 33
Worldwide total number of subjects	33
EEA total number of subjects	0

---

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	1
Adolescents (12-17 years)	1
Adults (18-64 years)	31

---

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Subjects were enrolled at 1 center in Vietnam.

### Pre-assignment

Screening details:

All subjects enrolled were included in the trial.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

The trial was designed as a single-arm, open-label study.

### Arms

Arm title	Agrippal
-----------	----------

Arm description:

Subjects received a single 0.5mL dose of Agrippal S1.

Arm type	Experimental
Investigational medicinal product name	Trivalent influenza virus vaccine (surface antigen, inactivated, egg derived)
Investigational medicinal product code	Agrippal
Other name	
Pharmaceutical forms	Suspension for injection in pre-filled syringe
Routes of administration	Intramuscular use

Dosage and administration details:

One dose of 0.5 mL

<b>Number of subjects in period 1</b>	Agrippal
Started	33
Completed	33

## Baseline characteristics

### Reporting groups

Reporting group title	Agrippal
-----------------------	----------

Reporting group description:

Subjects received a single 0.5mL dose of Agrippal S1.

Reporting group values	Agrippal	Total	
Number of subjects	33	33	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	1	1	
Adolescents (12-17 years)	1	1	
Adults (18-64 years)	31	31	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	26.48		
standard deviation	± 9.34	-	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	21	21	

### Subject analysis sets

Subject analysis set title	Enrolled Set
----------------------------	--------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

All enrolled subjects.

Subject analysis set title	Safety Set
----------------------------	------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

All enrolled subjects were included in the safety set.

Reporting group values	Enrolled Set	Safety Set	
Number of subjects	33	33	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	

Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	1	1	
Adolescents (12-17 years)	1	1	
Adults (18-64 years)	31	31	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous			
Units: years			
arithmetic mean	26.48	26.48	
standard deviation	± 9.34	± 9.34	
Gender categorical			
Units: Subjects			
Female	12	12	
Male	21	21	

## End points

### End points reporting groups

Reporting group title	Agrippal
Reporting group description:	
Subjects received a single 0.5mL dose of Agrippal S1.	
Subject analysis set title	Enrolled Set
Subject analysis set type	Safety analysis
Subject analysis set description:	
All enrolled subjects.	
Subject analysis set title	Safety Set
Subject analysis set type	Safety analysis
Subject analysis set description:	
All enrolled subjects were included in the safety set.	

### Primary: Number of subjects reporting solicited local and systemic reactions during the 7 days following one dose of Agrippal S1

End point title	Number of subjects reporting solicited local and systemic reactions during the 7 days following one dose of Agrippal S1 <sup>[1]</sup>
End point description:	
Safety was assessed as the number of subjects who reported solicited local and systemic reactions from day 1 through day 7 after the vaccination with of Agrippal S1. Analysis performed on the safety set.	
End point type	Primary
End point timeframe:	
Within 30 minutes after vaccination and for 7 days after vaccination	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There were no statistical analysis done.

End point values	Agrippal			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Number of subjects				
Any Reaction	13			
Any Local Reaction	11			
Any Systemic Reaction	7			
Any Severe Reaction	0			
Any Severe Local Reaction	0			
Any Severe Systemic Reaction	0			
Redness	3			
Swelling	1			
Injection site Pain 1 Pain when exposure	8			
Injection site Pain 2 Pain that impacts the normal	3			
Injection site Pain 3 Set obstacles to activities	0			
Fever from 38.5°C included to 39 °C	0			
Myalgia 1 Withstandable myalgia	4			
Myalgia 2 impacts the normal activities	2			
Myalgia 3 set obstacles to the normal activities	0			

Arthralgia 1 Withstandable arthralgia	1			
Arthralgia 2 impacts the normal activities	0			
Arthralgia 3 set obstacles to normal activities	0			
Malaise 1 Withstandable malaise	0			
Malaise 2 impacts the normal activities	0			
Malaise 3 set obstacles to the normal activities	0			
Headache 1 Withstandable headache	4			
Headache 2 impacts the normal activities	0			
Headache 3 set obstacles to the normal activities	0			
Nausea 1 Withstandable nausea	0			
Nausea 2 impacts the normal activities	0			
Nausea 3 set obstacles to the normal activities	0			
Vomiting 1 Withstandable vomiting	0			
Vomiting 2 impacts the normal activities	0			
Vomiting 3 set obstacles to the normal activities	0			
Diarrhea 1 Withstandable diarrhea	0			
Diarrhea 2 impacts the normal activities	0			
Diarrhea 3 set obstacles to the normal activities	0			
Stomachache 1 Withstandable stomachache	0			
Stomachache 2 impacts the normal activities	0			
Stomachache 3 set obstacles to normal activities	0			
Rash 1 Withstandable rash	0			
Rash 2 impacts the normal activities	0			
Rash 3 set obstacles to the normal activities	0			
Urticaria 1 In 01 specific area	0			
Urticaria 2 In 02 or 03 areas but not over 03	0			
Urticaria 3 In at least 04 areas	0			

## Statistical analyses

No statistical analyses for this end point

### Primary: Number of subjects reporting any unsolicited adverse events (AEs) after receiving one dose of Agrippal S1.

End point title	Number of subjects reporting any unsolicited adverse events (AEs) after receiving one dose of Agrippal S1. <sup>[2]</sup>
-----------------	---

End point description:

Safety was assessed as the number of subjects who reported unsolicited AEs up to approximately 30 days after the vaccination with of Agrippal S1. Analysis performed on the safety set.

End point type	Primary
----------------	---------



---

End point timeframe:

Approximately 30 days after vaccination.

---

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There were no statistical analysis done.

<b>End point values</b>	Agrippal			
Subject group type	Reporting group			
Number of subjects analysed	33			
Units: Number of subjects				
Any SAE	0			
Any unsolicited AE	0			
AEs leading to premature withdrawal	0			
Deaths	0			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All solicited AEs and unsolicited AEs were collected from Day 1 to Day 7; all other serious and non-serious AEs were collected for approximately 30 days after the vaccination.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	Agrippal
-----------------------	----------

Reporting group description:

Subjects received a single 0.5mL dose of Agrippal S1.

Serious adverse events	Agrippal		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 33 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Agrippal		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 33 (39.39%)		
Nervous system disorders			
Headache			
subjects affected / exposed	4 / 33 (12.12%)		
occurrences (all)	4		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	6 / 33 (18.18%)		
occurrences (all)	6		
Injection site erythema			
subjects affected / exposed	3 / 33 (9.09%)		
occurrences (all)	3		
Injection site pain			

subjects affected / exposed	11 / 33 (33.33%)		
occurrences (all)	11		
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	6 / 33 (18.18%)		
occurrences (all)	6		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The data-sets in this third-country study were manually computed. Please refer to the report submitted to the Vietnamese health authority for information (attached in the summary attachment section).
---

Notes: